Cost-Utility of Immunosuppressive Therapy Post-renal Transplantation in Saudi Arabia: The Saudi Ministry of Health Perspective

Objectives: Chronic kidney disease is ranked fourth among the top 10 causes of death in Saudi Arabia. Renal transplantation has been recognized as the treatment of choice compared with long-term dialysis to maintain graft survival and prolong a patient's healthy living. Immunosuppressants (ISs) must be administered lifelong. The choice between IS therapies can be challenging because of the similarity in efficacy with some differences in adverse events profile. The objective of this study was to assess the cost-effectiveness of different IS regimens in Saudi Arabia.Methods: A 25-year Markov model was developed based on a previously published study from the Saudi Ministry of Health payer perspective. Efficacy parameters were driven from the literature, whereas cost data were estimated from the Ministry of Health database. A Monte Carlo simulation was conducted to test the base-case model results' robustness.Results: All comparators resulted in 6.2 quality-adjusted life-years (QALYs) except for Advagraf (R) treatment (5.5 QALYs). Generic tacrolimus plus mycophenolate mofetil (MMF) will cost 70701.45 US dollars ($) (Saudi riyal 265130.44) per patient to gain 6.2 QALYs over 25 years' time horizon. In the improved adherence scenario, Envarsus (R) plus generic MMF generated 9.6 QALYs with a cost of $59 849 per patient. Monte Carlo simulation results have shown that generic tacrolimus is still the cheapest treatment option compared with other treatment arms.Conclusions: The current analysis suggested that all IS options are not cost-effective strategies relative to the willingness-to -pay threshold of $20 000. Nevertheless, Envarsus plus generic MMF regimen could become the most cost-effective regimen at different willingness-to-pay thresholds.